SCHEMBL5337267

SCHEMBL5337267

CCCCN(c1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1)S(C)(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 4/20 0.52
CKS1B P61024 2/20 0.42
SKP1 P63208 2/20 0.42
SKP2 Q13309 2/20 0.42
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR2 P34972 1/20 0.41
POLB P06746 1/20 0.41
GPR119 Q8TDV5 3/20 0.41
HSD17B10 Q99714 1/20 0.41
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
LMNA P02545 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5335663 0.89 MC4R (0.55) MC4RCKS1BSKP1SKP2GAA
SCHEMBL5338171 0.87 MC4R (0.53) MC4RCKS1BSKP1SKP2MEN1
SCHEMBL5331626 0.84 MC4R (0.55) MC4RCKS1BSKP1SKP2GAA
SCHEMBL5346578 0.84 MC4R (0.57) MC4RMEN1MAPTTSHRHTT
SCHEMBL5332549 0.83 MC4R (0.70) MC4R
SCHEMBL5338150 0.82 MC4R (0.65) MC4R
SCHEMBL4520958 0.81 MC4R (0.49) MC4RCKS1BSKP1SKP2GAA
SCHEMBL14355843 0.81 DRD2 (0.44) MC4RMAPTKMT2AHSD17B10LMNA
SCHEMBL5338194 0.81 MC4R (0.64) MC4R
SCHEMBL14356035 0.78 ADRB1 (0.42) MC4RMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R MC4R 2/4885CKS1B 4539/4885SKP1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.